Currently available bDMARDs for inflammatory rheumatic diseases

What biologic agents (biologic disease-modifying antirheumatic drugs [bDMARDs]) are currently available for use in the treatment of inflammatory rheumatic diseases?

With our increased understanding of the pathogenesis of autoimmune rheumatic diseases, several bDMARDs have been developed for treatment, especially for RA, ankylosing spondylitis (AS), psoriatic arthritis (PsA), juvenile idiopathic arthritis (JIA), cryopyrinopathies/cryopyrin-associated autoinflammatory syndromes (CAPS), systemic lupus erythematosus (SLE), and primary vasculitides. These can be classified as follows:

  • Cytokine-targeted therapies:
  • • TNF-α inhibitors: etanercept (ETN), infliximab (INF), adalimumab (ADA), golimumab, certolizumab.
  • • TNF-α inhibitor biosimilars: ETN-szzs, ETN-ykro, INF-dyyb, INF-abba, INF-qbtx, ADA-atto, ADA-abdm, ADA-adaz.
  • • IL-1 inhibitors: anakinra, rilonacept, canakinumab.
  • • Anti-IL-5: mepolizumab. Anti-IL-5 receptor: berralizumab.
  • • Anti-IL-6 receptor: tocilizumab, sarilumab. Anti-IL-6: siltuximab.
  • • Anti-IL-12/IL-23: ustekinumab.
  • • Anti-IL-17A: secukinumab, ixekizumab. Anti-IL-17 receptor: brodalumab.
  • • Anti-IL-23: guselkumab, tildrakizumab, risankizumab.
  • B-cell-targeted therapies:
  • • Rituximab (RTX, anti-CD20),ocrelizumab (anti-CD20)
  • • B-cell growth factor inhibitors: belimumab (anti-Blys).
  • T-cell-targeted therapies:
  • • Costimulatory molecule inhibitors: abatacept (anti-CD80/86).
  • Complement-targeted therapies:
  • • Eculizumab (anti-C5).
15585

Sign up to receive the trending updates and tons of Health Tips

Join SeekhealthZ and never miss the latest health information

15856
Scroll to Top